484-27-5

Basic information

• Product Name: 1-(6-hydroxy-4-methoxy-1-benzofuran-5-yl)ethanone
• Synonyms: 1-(6-Hydroxy-4-methoxy-5-benzofuranyl)ethanone; ethanone, 1-(6-hydroxy-4-methoxy-5-benzofuranyl)-
• CAS NO: 484-27-5
• Molecular Formula: C₁₁H₁₀O₄
• Molecular Weight: 206.1947
• Mol File: 484-27-5.mol
• Article Data: 18

Chemical Properties

• Melting Point: 108-109 °C
• Boiling Point: 213.4°C at 760 mmHg
• Flash Point: 82.9°C
• Density: 1.286g/cm³
• Vapor Pressure: 0.113mmHg at 25°C
• Refractive Index: 1.601
• PKA: 9.15±0.40(Predicted)
• CAS DataBase Reference: 1-(6-hydroxy-4-methoxy-1-benzofuran-5-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(6-hydroxy-4-methoxy-1-benzofuran-5-yl)ethanone(484-27-5)
• EPA Substance Registry System: 1-(6-hydroxy-4-methoxy-1-benzofuran-5-yl)ethanone(484-27-5)

Safety Data

• Hazardous Substances Data: 484-27-5(Hazardous Substances Data)

Upstream product

• 82-57-5 visnagin 

Downstream Products

• 55008-22-5 1-(6-hydroxy-4-methoxy-benzofuran-5-yl)-3t-(4-hydroxy-3-methoxy-phenyl)-propenone 
• 73877-30-2 3t-(4-dimethylamino-phenyl)-1-(6-hydroxy-4-methoxy-benzofuran-5-yl)-propenone 
• 110480-76-7 1-{7-[(Dibenzylamino)-methyl]-6-hydroxy-4-methoxy-benzofuran-5-yl}-ethanone 
• 110469-35-7 1-[6-Hydroxy-4-methoxy-7-(4-phenyl-piperidin-1-ylmethyl)-benzofuran-5-yl]-ethanone 
• 92663-28-0 C₂₃H₁₉O₄P 
• 187242-01-9 C₁₇H₁₈O₄ 
• 181180-01-8 1-{4-[1-(6-Hydroxy-4-methoxy-benzofuran-5-yl)-eth-(E)-ylideneamino]-phenyl}-ethanone 
• 54437-44-4 1-(6-hydroxy-4-methoxy-benzofuran-5-yl)-3t-phenyl-propenone 

Relevant articles and documents

Synthesis of new furothiazolo pyrimido quinazolinones from visnagenone or khellinone and antimicrobial activity

Substituted-6-methyl-1-thioxo-1,2-dihydro-3H-furo[3,2-g]pyrimido[1,6-a]quinazolin-3-ones (5a,b) were synthesized from condensation of visnagenone (2a) or khellinone (2b) with 6-amino-thiouracil (3) in dimethylformamide or refluxing of (4a) or (4b) in dimethylformamide. Hence, compounds (5a,b) were used as the starting materials for preparing many new heterocyclic compounds such as; furo[3,2-g]pyrimido[1,6-a]quinazoline (6a,b), furo[3,2-g]thiazolo[20,30:2,3] pyrimido[1,6-a]quinazolinone (7a,b), substituted-benzylidene-furo[3,2-g]thiazolo[20,30:2,3]pyrimido [1,6-a]quinazoline-3,5-dione (8a-f), 3-oxo-furo[3,2-g]pyrimido[1,6-a]quinazoline-pentane-2,4-dione (9a,b), 1-(pyrazole)-furo[3,2-g]pyrimido[1,6-a]quinazolinone (10a,b), 2-(oxo or thioxo)-pyrimidinefuro[ 3,2-g]pyrimido[1,6-a]quinazolinone (11a-d), 1-(methylthio)-furo[3,2-g]pyrimido[1,6-a] quinazolinone (12a,b), 1-(methyl-sulfonyl)-furo[3,2-g]pyrimido[1,6-a]quinazolinone (13a,b) and 6-methyl-1-((piperazine) or morpholino)-3H-furo[3,2-g]pyrimido[1,6-a]quinazolin-3-one (14a-d). The structures of the prepared compounds were elucidated on the basis of spectral data (IR, 1H-NMR, 13C-NMR, MS) and elemental analysis. Antimicrobial activity was evaluated for the synthesized compounds against Gram-positive, Gram-negative bacteria and fungi. The new compounds, furothiazolo pyrimido quinazolines 8a-f and 11a-d displayed results excellent for growth inhibition of bacteria and fungi.

Synthesis of new quinoxaline, pyrimidine, and pyrazole furochromone derivatives as cytotoxic agents

Abstract: A series of novel quinoxaline, pyrimidine, and pyrazole furochromone derivatives were synthesized for the first time. These derivatives were prepared under mild conditions using a stepwise efficient methodology. The developed protocol led to the synthesis of furochromone derivatives in moderate to good yields (60–75%). The structures of the prepared derivatives were identified using several spectroscopic techniques including IR, NMR, and mass spectrometry. The cytotoxic activity of the synthesized derivatives was evaluated using in vitro Ehrlich ascites assay. Pyrazolobenzofurans exhibited the most potent effect suggesting the importance of pyrazole nucleus for the cytotoxic activity. Graphical abstract: [Figure not available: see fulltext.].

-

-

Antitumor and multikinase inhibition activities of some synthesized coumarin and benzofuran derivatives

Two new series of coumarin and benzofuran derivatives were designed, synthesized, and assessed for their in vitro and in vivo antitumor activities against breast cancer. Compounds 8, 9, 14, 15, and 17 exhibited the best antiproliferative activities (IC50: 0.07?2.94 μM) against the MCF-7 cell line, compared with lapatinib (IC50: 4.69 μM). Compound 14, with the most potent cytotoxic activity against MCF-7 cells, was capable of enhancing preG1 apoptosis and triggering cell cycle arrest at the G2/M phase. The kinase inhibitory activity of compound 14 against a panel of 22 kinases was examined to reveal multikinase inhibition within ?39% to ?97%. Furthermore, compound 14 exhibited potent in vivo Ehrlich (mammary adenocarcinoma) tumor regression, positive caspase-3, and negative EGFR immunoreaction, and was capable of elevating the catalase level. The physicochemical properties and pharmacokinetic parameters of compound 14 were investigated in silico for its druglikeness.

Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds

Two new series of furochromone and benzofuran derivatives were designed, synthesized and evaluated for their in vitro anticancer activity against MCF-7 and MDA231 breast cancer cell lines. Compounds 5, 6, 7, 9, 15a, 16, 17a and 18 exhibited the best antip